7 active not recruiting, 3 completed, 2 withdrawn, 1 recruiting. 15 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Active not recruiting 7, Completed 3, Withdrawn 2, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 2 | Withdrawn 2 |
| Phase 1 | 1 | Completed 1 |
Follow REM Sleep Behavior Disorder: new trials by email Literature Review of REM Sleep Behavior Disorder trials Research Report on REM Sleep Behavior Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) Adalimumab, Placebo - REM Sleep Behavior Disorder | Phase 2 | Recruiting | Yale University | 108 | 2026-08-17 | 2026-11-09 |
| IMPACT 360 for Parkinson's Disease Exercise, Meditation, Diet - Parkinson's Disease (PD), REM Sleep Behavior Disorder | Phase 2 | Active not recruiting | University of British Columbia | 60 | 2024-10-28 | 2026-06-25 |
| Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder PXS-4728 (A), Matching Placebo (B) - REM Sleep Behavior Disorder | Phase 2 | Active not recruiting | Syntara | 40 | 2023-11-08 | 2026-06-02 |
| Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease Rasagiline - REM Sleep Behavior Disorder, Parkinson Disease | Phase 2 / Phase 3 | Withdrawn | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2023-01-01 | 2025-01-07 | |
| Terazosin and Parkinson's Disease Extension Study Terazosin therapy - Symptomatic Parkinson Disease, REM Sleep Behavior Disorder | Phase 2 | Active not recruiting | Cedars-Sinai Medical Center | 15 | 2022-09-23 | 2026-03-02 |
| Terazosin Effect on Cardiac Changes in Early Parkinson's Disease Terazosin - REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease | Phase 2 | Active not recruiting | Cedars-Sinai Medical Center | 15 | 2020-11-01 | 2026-03-02 |
| A Clinical Study of the Efficacy of Idebenone in the Treatment of iRBD Into Synucleinopathies Idebenone, Placebo - Rapid Eye Movement Sleep Behavior Disorder, Synucleinopathy | Phase 2 | Active not recruiting | Ruijin Hospital | 28 | 2020-08-31 | 2025-11-25 |
| A Study of Efficacy and Safety of Idebenone Vs. Placebo in Prodromal Parkinson Disease Idebenone, Placebo oral tablet - REM Sleep Behavior Disorder, Parkinson Disease | Phase 2 / Phase 3 | Withdrawn | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2020-01-01 | 2025-01-07 | |
| Cardiac Changes in Early Parkinson's Disease: A Follow up Study Carvedilol - REM Sleep Behavior Disorder, Pre-motor Parkinson Disease | Phase 2 | Active not recruiting | Cedars-Sinai Medical Center | 15 | 2019-12-30 | 2026-03-02 |
| Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136) Carvedilol - REM Sleep Behavior Disorder, Pre-motor Parkinson Disease | Phase 2 | Active not recruiting | Michele Tagliati, MD | 15 | 2019-04-04 | 2026-03-02 |
| Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls (11C)PE2I, Ioflupane - Parkinson Disease, REM Sleep Behavior Disorder | Phase 1 / Phase 2 | Completed | Weill Medical College of Cornell University | 82 | 2018-08-14 | 2025-03-12 |
| Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder Nelotanserin - Lewy Body Dementia, Dementia With Lewy Bodies | Phase 2 | Terminated | Axovant Sciences Ltd. | 80 | 2016-10-20 | 2019-03-27 |
| Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease Melatonin PR, Clonazepam, Melatonin PR placebo - REM Sleep Behavior Disorder, Parkinson Disease | Phase 2 | Unknown | Seoul National University Hospital | 30 | 2016-07-01 | 2016-06-03 |
| Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) Nelotanserin, Placebo - Dementia With Lewy Bodies, REM Sleep Behavior Disorder | Phase 2 | Completed | Axovant Sciences Ltd. | 34 | 2016-03-01 | 2020-05-20 |
| Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism Clonazepam, Placebo - REM Sleep Behavior Disorder | Phase 2 | Completed | Seoul National University Hospital | 40 | 2015-03-01 | 2016-04-25 |
Parkinson Disease (8) · Parkinson Disease, Secondary (4) · Synucleinopathies (3) · Lewy Body Disease (2) · Nerve Degeneration (2) · Primary Dysautonomias (2) · Hallucinations (1) · Motor Activity (1)
Mental Disorders (15) · Nervous System Diseases (15) · Parasomnias (15) · REM Sleep Parasomnias (15) · Sleep Wake Disorders (15) · Basal Ganglia Diseases (12) · Brain Diseases (12) · Central Nervous System Diseases (12) · Movement Disorders (12) · Neurodegenerative Diseases (12) · Parkinsonian Disorders (12) · Synucleinopathies (9) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Pathological Conditions, Signs and Symptoms (3)
Carvedilol (2) · Clonazepam (2) · idebenone (2) · nelotanserin (2) · Adalimumab (1) · Diet (1) · Exercise (1) · Magnetic Resonance Spectroscopy (1) · Meditation (1) · Melatonin (1) · N-(3-iodoprop-2-enyl)-2-beta-carbomethoxy-3-(4-methylphenyl)nortropane (1) · Terazosin (1) · ioflupane (1) · rasagiline (1)
Cedars-Sinai Medical Center (3) · Axovant Sciences Ltd. (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Seoul National University Hospital (2) · Michele Tagliati, MD (1) · Ruijin Hospital (1) · Syntara (1) · University of British Columbia (1) · Weill Medical College of Cornell University (1) · Yale University (1)
United States (8) · Canada (2) · China (2) · South Korea (2) · Australia (1) · United Kingdom (1)
Baorong Zhang, MD (2) · Ilise Lombardo, MD (2) · Michele Tagliati, MD, FAAN (2) · Alexander Shtilbans, MD (1) · Beom Seok Jeon, MD, Ph.D (1) · Beomseok Jeon, MD, PhD (1) · Jesse Cedarbaum, MD (1) · Michele L Lima Gregorio, MD, FAAN (1) · Michele L Tagliati, MD (1) · Silke Appel-Cresswell, MD, FRCPC (1)
PMID 10214756, PMID 10406987, PMID 10527042, PMID 10853813, PMID 10979878, PMID 11076832, PMID 11400186, PMID 11724917, PMID 12498954, PMID 12904089, PMID 15175402, PMID 15345186, PMID 15645531, PMID 15779234, PMID 16025231, PMID 16442563, PMID 16715205, PMID 16837857, PMID 17190953, PMID 18079166, PMID 18349024, PMID 19018276, PMID 20146689, PMID 20188504, PMID 20846908, PMID 20887968, PMID 20976736, PMID 21045744, PMID 21421334, PMID 21538520, PMID 21571570, PMID 21700495, PMID 21802993, PMID 22321865, PMID 22483040, PMID 22508280, PMID 23024438, PMID 23160999, PMID 23266935, PMID 23329524, PMID 23347909, PMID 23562390, PMID 23647842, PMID 23970363, PMID 24332912, PMID 24637128, PMID 25483722, PMID 25589269, PMID 25666029, PMID 25681454
R01AG095016 (1), R01NS095562 (1)